Your session is about to expire
← Back to Search
Long-Term Follow-Up of Patients who Received ATL001 for Non-Small Cell Lung Cancer and Melanoma
Study Summary
This trial is looking at the long-term safety and effectiveness of a drug that has been previously administered to patients in other studies.
- Melanoma
- Non-Small Cell Lung Cancer
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- You have participated in a previous clinical trial that tested ATL001 called ATX-NS-001 or ATX-ME-001.
- Group 1: Experimental: ATL001
- Group 2: Patients who have previously received ATL001 in study ATX-NS-001 or study ATX-ME-001
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Is there still room for participants in this trial?
"Clinicaltrials.gov reveals that this medical study, which was originally posted on June 1st 2022 and last updated February 15th 2022 is no longer actively recruiting participants. Nevertheless, a plethora of other studies are currently searching for individuals to join their trial - 2060 in total."
What are the chief objectives of this experiment?
"According to the study's sponsor, Achilles Therapeutics UK Limited, its main objective is assessment of autoimmune adverse events over a span lasting between 4 months and 84 months (or until death or the end of the trial). Secondary outcomes which will be monitored include duration of response as assessed by investigator and independent central review per RECIST v1.1; progression-free survival; and long-term requirements for cancer-related medical resources post ATL001 therapy."
Share this study with friends
Copy Link
Messenger